Skip to content

Study · Randomized controlled trial · n = 44 · 2023

7 results

Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.

Mashayekhi M, Beckman JA, Nian H, Garner EM, Mayfield D, Devin JK, Koethe JR, Brown JD, Cahill KN, Yu C, Silver H, Niswender K, Luther JM, Brown NJ

Diabetes, obesity & metabolism10 Nov 2022Cited by 33 (Europe PMC)

PMID36306151 (opens in a new tab)PMCIDPMC10306232 (opens in a new tab)DOI10.1111/dom.14903 (opens in a new tab)PepBankPUB-36306151
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, liraglutide reduced PAI-1 over 14 weeks; sitagliptin did not.

    In plain wordsIn adults with obesity and prediabetes, liraglutide lowered the clotting-related marker PAI-1; sitagliptin did not.

    Peptide
    Liraglutide
    Outcome
    DecreasePAI-1
    Study

    n = 44

    Analysis
    Primary
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    The primary outcomes were measures of endothelial function: flow-mediated vasodilation (FMD), plasminogen activator inhibitor-1 (PAI-1) and urine albumin-to-creatinine ratio (UACR).
    2 context sentences
    Summary · context
    Liraglutide and diet reduced weight, insulin resistance and PAI-1, while sitagliptin did not.
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, liraglutide had no significant effect on endothelial vasodilator function measured by FMD.

    In plain wordsIn adults with obesity and prediabetes, liraglutide did not significantly change blood vessel dilation (FMD).

    Peptide
    Liraglutide
    Outcome
    No significant changeFlow-mediated vasodilation (FMD)
    Study

    n = 44

    Analysis
    Primary
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant effect of any treatment on endothelial vasodilator function measured by FMD.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, UACR did not change with any treatment, including liraglutide, diet or sitagliptin.

    In plain wordsIn adults with obesity and prediabetes, liraglutide did not change the urine albumin-to-creatinine ratio.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrine albumin-to-creatinine ratio (UACR)
    Study

    n = 44

    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    The primary outcomes were measures of endothelial function: flow-mediated vasodilation (FMD), plasminogen activator inhibitor-1 (PAI-1) and urine albumin-to-creatinine ratio (UACR).
    2 context sentences
    Summary · context
    There was no effect of treatment on UACR.
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In a post hoc subgroup with baseline FMD below the median, liraglutide improved FMD, as did diet and sitagliptin.

    In plain wordsIn a post hoc subgroup with poorer vessel function, blood vessel dilation improved on liraglutide, and also on diet and sitagliptin.

    Peptide
    Liraglutide
    Outcome
    IncreaseFMD in individuals with baseline FMD below the median
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Post hoc subgroup analyses in individuals with baseline FMD below the median, indicative of greater endothelial dysfunction, showed an improvement in FMD by all three treatments.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, liraglutide reduced body weight over 14 weeks.

    In plain wordsIn adults with obesity and prediabetes, liraglutide lowered body weight over 14 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 44

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide and diet reduced weight, insulin resistance and PAI-1, while sitagliptin did not.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, liraglutide reduced insulin resistance over 14 weeks.

    In plain wordsIn adults with obesity and prediabetes, liraglutide lowered insulin resistance over 14 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin resistance
    Study

    n = 44

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide and diet reduced weight, insulin resistance and PAI-1, while sitagliptin did not.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, liraglutide, but not sitagliptin or diet, reduced the chemokine MCP-1.

    In plain wordsIn adults with obesity and prediabetes, liraglutide lowered the inflammation marker MCP-1; sitagliptin and diet did not.

    Peptide
    Liraglutide
    Outcome
    DecreaseMCP-1
    Study

    n = 44

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Finally, liraglutide, but not sitagliptin or diet, reduced the chemokine monocyte chemoattractant protein-1 (MCP-1).
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.